Aptevo Therapeutics
APVO
10 hedge funds and large institutions have $231K invested in Aptevo Therapeutics in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
11% more funds holding
Funds holding: 9 → 10 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
61% less capital invested
Capital invested by funds: $599K → $231K (-$368K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$147K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$36.8K |
| 3 |
Renaissance Technologies
New York
|
+$13.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.21K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$9.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$229K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$153K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$41.4K |
| 4 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$5.02K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$153 |
APVO Hedge Fund Activity: Q3 2024 in Review
10 of the 6,966 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q3 2024, worth a combined $231K — down 61% from $599K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new APVO positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Hudson Bay Capital Management, adding an estimated $147K. The largest seller was Armistice Capital, exiting entirely with an estimated $229K sold.
- 10 institutional investors held Aptevo Therapeutics (APVO) as of Q3 2024, up from 9 in Q2 2024.
- Funds reported $231K of Aptevo Therapeutics stock for Q3 2024, down 61% quarter-over-quarter.
- 5 funds opened new Aptevo Therapeutics positions in Q3 2024 and 4 closed out, a net change of +1 holder.
- The largest Aptevo Therapeutics buyer in Q3 2024 was Hudson Bay Capital Management, an estimated $147K added.
- The largest Aptevo Therapeutics seller in Q3 2024 was Armistice Capital, an estimated $229K sold.
Based on aggregated 13F filings for Q3 2024.